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e-mail address: drghasemi@yahoo.com (K.G. Falavarjani).Khalil Ghasemi Falavarjani ⇑; Joobin Khadamy; Arezoo Karimi Moghaddam; Nasser Karimi; Mehdi ModarresAbstractPurpose: To evaluate the short-term results of sub-tenon’s injection of bevacizumab in patients with clinically significant macular
edema (CSME).
Methods: In this prospective non-comparative interventional case series, sub-tenon’s injection of 2.5 mg/0.1 ml bevacizumab was
performed for eyes with CSME. Macular thickness and best corrected visual acuity measurements were performed before and one
month after injections.
Results: Nineteen eyes of twelve patients with a mean age of 59.8 ± 5.7 years were evaluated. Thirteen eyes (68.4%) had
center-involving macular edema. No significant difference was observed between pre- and post-injection central subfield retinal
thickness measurements (P = 0.3). Central subfield thickness measurements improved or remained unchanged in 13 eyes (68.4%).
Baseline BCVA of 0.48 ± 0.35 LogMAR improved to 0.36 ± 0.26 LogMAR after injection (P = 0.01). Improvement of >2 lines in
BCVA was found in 5 eyes (26.3%), and no eye lost >2 lines of BCVA. No complication associated with sub-tenon’s injection
was observed.
Conclusion: Sub-tenon’s injection of bevacizumab resulted in significant short-term visual improvement in eyes with CSME. Retinal
thickness changes were not significant.
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Macular edema is one of the main causes of visual
impairment in patients with diabetic retinopathy.1 The
Early Treatment Diabetic Retinopathy Study (ETDRS)
showed that macular photocoagulation reduced the risk
of moderate visual acuity loss in eyes with clinically
significant macular edema (CSME) by approximately 50%.2
The aim of the macular photocoagulation treatment in
CSME is to prevent further visual loss and improvement
of visual acuity occurs in about 10–20% of eyes.2–4
Treatment of diabetic macular edema with anti-vascularendothelial growth factor (VEGF) agents has resulted in
superior outcomes compared to conventional laser
photocoagulation. Currently, the treatment of choice for
diffuse diabetic macular edema is intravitreal injection
of anti-VEGF agents alone or in combination with laser
photocoagulation.5,6
Although previous studies have shown the efficacy of
intravitreal anti-VEGF injections in various retinal diseases,
each intravitreal injection poses the risk of post-injection ocu-
lar adverse events including infectious endophthalmitis,
intraocular inflammation, intraocular pressure elevation and
retinal detachment.7e:
al.com
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delivery of various medications into the eye.8 Promising
results have been reported with sub-tenon’s injection of tri-
amcinolone for the treatment of diabetic macular edema.9,10
Liang et al.11 reported successful treatment of myopic choroi-
dal neovascularization (CNV) with posterior sub-tenon’s
bevacizumab (STB) injection. To our knowledge, no other
study has reported the use of sub-tenon’s injection of anti-
VEGF agents in ocular diseases. The aim of this pilot study
was to evaluate the results of STB injections in eyes with
CSME. If found useful, the STB is a less invasive alternative
for the treatment of diabetic macular edema as compared
to intravitreal injections.Methods
In this prospective non-comparative interventional case
series, from January to May 2014, all patients with clinically
significant diabetic macular edema (according to EDTRS clas-
sification)2 who underwent STB injection were included. We
considered STB injection for eyes with non-center involved
macular edema who were candidate for macular photocoag-
ulation.3,4 Patients with center involving macular edema who
were eligible for intravitreal anti-VEGF therapy but rejected
the intravitreal injections due to the possible complications
associated with intravitreal injections, were also considered
for STB treatment. Macular photocoagulation was performed
for all patients one month after STB injections. The study pro-
tocol was approved by the Rassoul Akram Hospital Eye
Research Center Ethics Committee and informed consents
were obtained.
Exclusion criteria were the history of intraocular surgery
during last 8 months, history of retinal laser photocoagula-
tion, high refractive errors (>6 diopters of sphere or >3 diop-
ters of cylinder), media opacity affecting visual acuity and
optical coherence tomography (OCT) measurements, history
of glaucoma or intraocular pressure more than 22 mmHg,
ischemic or inflammatory optic neuropathy, uveitis, retinal
vascular occlusion, vitreomacular interface disorders and
the need for panretinal photocoagulation. Both eyes of each
participant were enrolled if both eyes met the inclusion
criteria.
Complete ophthalmic examination including best cor-
rected visual acuity measurement (BCVA) using a standard
Snellen chart (converted to LogMAR), and slit lamp and
dilated fundus examination was performed. Macular thick-
ness measurements were taken with a 3D spectral domain
OCT-1000 device (software version 3.32.003.04, Topcon
Incorporation, Tokyo, Japan). A 3D Scan 512  128 protocol,
covering a 6  6 mm2 centered on the fovea was used for all
measurements. Images with inadequate quality factor (<45),
discontinuity, misalignment, involuntary saccade or blinking
artifacts were excluded. OCT imaging and BCVA measure-
ments were taken immediately before and one month after
STB injections.
All injections were performed in the office. After instilla-
tion of a drop of tetracaine, one drop of 5% povidone-iodine
was instilled in the fornix. The lids were kept open by the
surgeon and no speculum was used. The patients were asked
to look at the contralateral shoulder. The injections were
performed into the sub-tenon’s space in the superotemporal
fornix (as far posteriorly as could be easily visualized, nearlymore than 8 mm from limbus) with a 27-gauge needle
under direct visualization. Each injection consisted of
2.5 mg bevacizumab in 0.1 mm volume.
Statistical analyses were performed with a SPSS software
(version 15, SPSS Inc. Chicago, IL) and paired t test and cor-
relation test were used for analysis. P < 0.05 was considered
significant. The average retinal thickness in central 1 mm and
3 mm of the OCT macular grid was considered central sub-
field thickness (CST) and central macular thickness (CMT),
respectively. Considering the intersession repeatability of
the OCT instrument, CST changes >14.5 lm were considered
clinically significant.12Results
Nineteen eyes of twelve patients including 5 men and 7
women with a mean age of 59.8 ± 5.7 years were assessed.
Thirteen eyes (68.4%) had center-involving macular edema.
Central subfield retinal thickness was 350.7 ± 113.3 lm
and 337.6 ± 109.7 lm before and one month after injections,
respectively (P = 0.3). Mean change in CST was
13.1 ± 61.5 lm. Seven eyes (36.8%) had a clinically signifi-
cant decrease in CST and a clinically significant increase in
CST was observed in 6 eyes (31.5%). Central macular thick-
ness was 362.4 ± 68.7 lm and 355.4 ± 63.5 lm before and
after injections, respectively (P = 0.2).
Baseline BCVA of 0.48 ± 0.35 LogMAR improved to
0.36 ± 0.26 LogMAR after injection (P = 0.01). Mean change
in BCVA was 0.12 ± 0.19 LogMAR. Improvement and wors-
ening of BCVA was found in 10 (52.6%) and 2 eyes (10.5%),
respectively. Improvement of >2 lines in BCVA was found in
5 eyes (26.3%), and no eye lost >2 lines of BCVA.
Improvement in BCVA was statistically significantly corre-
lated with decrease in CST (P = 0.003).
No complication associated with STB injection including
scleral perforation, infection or limitation in ocular move-
ments was observed.Discussion
Although intravitreal injection is the most frequently used
method of anti-VEGF application in ophthalmology, alterna-
tive routes have been evaluated. Several studies reported
successful application of topical and subconjunctival beva-
cizumab for corneal neovascularization.13–15 Kim et al.16
reported that bevacizumab penetrated into the anterior
chamber of the rabbits after a single subconjunctival injection
of 2.5 mg of bevacizumab. Nomoto et al.17 evaluated the
pharmacokinetics of bevacizumab in rabbit eyes and showed
a maximum concentration of 1418.7 and 295.8 ng/g in the
iris/ciliary body and retina/choroid, respectively, after sub-
conjunctival injection of 1.25 mg of bevacizumab. They
showed that the bevacizumab level in the retina/choroid
and iris/ciliary body was maintained above half-maximum
inhibitory concentration for 8.6 and 8.4 weeks, respectively.
Moreover, they found longer half-life for bevacizumab in
the iris/ciliary body and retina/choroid after subconjunctival
injection compared with those after intravitreal injection.
They proposed that this may be secondary to the sustained
bevacizumab delivery into the intraocular tissues due to the
scleral depot binding of bevacizumab to the scleral matrix.
Ryoo et al.18 reported three eyes with neovascular glaucoma
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after subconjunctival bevacizumab injection. Recently, Liang
et al.11 evaluated the effect of STB injection for the treatment
of 9 eyes with myopic CNV. All nine eyes were injected with
12.5 mg of STB with repeated injections after 2 weeks for
some cases. They reported complete absorption of subreti-
nal fluid in 8 eyes.
Previous studies have reported a significant decrease in
macular thickness in the untreated fellow eye after intravitreal
administration of anti-VEGF agents.19,20 A small but effective
part of the drug may escape into the systemic circulation and
reach the retina via retinal vessels. This may be considered as
an alternative explanation for the effect of the sub-tenon’s
bevacizumab injection.
Our study showed a non-significant reduction of
13.1 ± 61.5 lm in mean CST after STB injections. Similarly,
previous studies have reported a non-significant decrease
in macular thickness after macular photocoagulation with or
without sub-tenon’s injection of triamcinolone acetonide in
eyes with CSME.21–23 We found significant improvement in
BCVA, though, one month after STB injection. Mean
improvement in BCVA was 0.12 ± 0.19 LogMAR and
improvement of >2 lines of BCVA was found in 26.3%. This
is apparently superior to the visual acuity response after mac-
ular photocoagulation with or without sub-tenon’s injection
of triamcinolone acetonide as well as natural course of
CSME.21–24 Soheilian et al.22 reported a mean change of
0.18 ± 0.19, 0.11 ± 0.21 and 0.06 ± 0.19 LogMAR,
6 weeks after intravitreal bevacizumab, intravitreal triamci-
nolone acetonide and macular photocoagulation, respec-
tively. They found improvement of >2 lines in 27.9%,
26.3%, and 5.1%, respectively.
We found a significant improvement in BCVA despite non-
significant reduction in CST. Previous studies have shown
that the correlation between BCVA and retinal thickness
measurements is not always significant and the morphologic
characteristics of the retina including integrity of outer layers,
the presence of subretinal fluid and the shape of cystoid
spaces are more important determinants.25–27 Alternatively,
small sample size may explain non-significant reduction in
CST in our study.
Our study has several limitations. The sample size is small.
The follow up was short. We did not measure the level of the
vitreous and anterior chamber VEGF. Also, this is a non-
comparative study without a matched control group.
Despite these limitations, this is the first study suggesting a
possible role for STB injection in CSME. Intravitreal injection
of anti-VEGF agents may be associated with specific compli-
cations related to the injections, including endophthalmitis,
intraocular inflammation and trauma to the lens. The
repeated need for injections increases the risk of adverse
events. Moreover, many surgeons believe that the injections
should be performed in the operating room. Although the
effect of STB injection on the retinal thickness seems to be
lower than intravitreal injection, it may serve as a safe alterna-
tive for intravitreal injection of bevacizumab in a subset of
patients who are not feeling comfortable with intravitreal
injections. Moreover, higher doses of STB may have an effect
comparable to intravitreal injection. Further controlled
studies are needed to elucidate the results of this study. The
pharmacokinetics of the bevacizumab after subconjunctival
injection has been previously described.17 Consideringanatomical differences between rabbits and humans, addi-
tional studies are required to show the pharmacokinetics of
the drug after sub-tenon’s injection.Financial Interest
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